SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Jay Fram

245

Biogen

BIIB

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases, and hemophilia. It also makes and sells biosimilars of advanced biologics.

Looking for leads, investment insights, or competitive intelligence?

CEO

Michel Vounatsos

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Cambridge, Mass.

Years on Fortune 500 List

9

Employees

7,300

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$12,2747.2%
Profits ($M)$2,539.1-31.4%
Assets ($M)$23,653
Total Stockholder Equity ($M)$12,613
Market Value — as of March 29, 2018 ($M)$57,930
Profit Ratios
Profit as % of Revenues20.7%
Profits as % of Assets10.7%
Profits as % of Stockholder Equity20.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)11.92
EPS % Change (from 2016)-29.6%
EPS % Change (5 year annual rate)15.7%
EPS % Change (10 year annual rate)19.6%
Total Return
Total Return to Investors (2017)21.8%
Total Return to Investors (5 year, annualized)18.7%
Total Return to Investors (10 year, annualized)19.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Biogen

The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →
Alzheimer's Cases Are Expected to Double By 2060 and We're Not Ready for It

There still aren't any truly effective drugs for Alzheimer's or dementia.

Read More →
Could a New Immunotherapy Medical Approach Break the Alzheimer's Drug Curse?

AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.

Read More →